Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 3/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | TLR4 | O00206 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17154090 | 0.92 | ALDH1A1 (0.43) | ATMALDH1A1KDM4EMAPTKMT2A | |
| SCHEMBL12331137 | 0.86 | — | — | |
| SCHEMBL12409239 | 0.86 | — | — | |
| SCHEMBL12332204 | 0.86 | — | — | |
| SCHEMBL284319 | 0.82 | ATM (0.56) | ATMALDH1A1KDM4EMTNR1AMTNR1B | |
| SCHEMBL284342 | 0.82 | ATM (0.56) | ATMALDH1A1KDM4EMTNR1AMTNR1B | |
| SCHEMBL50350 | 0.82 | — | — | |
| SCHEMBL284318 | 0.82 | ATM (0.56) | ATMALDH1A1KDM4EMTNR1AMTNR1B | |
| Water SCHEMBL27364290 | 0.79 | — | — | |
| Hydrochloric Acid SCHEMBL27752288 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 180 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016124553-A1 | 2-PHENYL-3H-IMIDAZO[4,5-B]PYRIDINE DERIVATES USEFUL AS INHIBITORS OF MAMMALIAN TYROSINE KINASE ROR1 ACTIVITY | KANCERA AB (SE) | 2016-08-11 | — | — | WO | claimed |
| EP-2678342-A1 | N-SUBSTITUTED OXAZINOPTERIDINES AND OXAZINOPTERIDINONES | Takeda Pharmaceutical Company Limited (JP) | 2014-01-01 | — | — | EP | claimed |
| WO-2012148548-A1 | N-SUBSTITUTED OXAZINOPTERIDINES AND OXAZINOPTERIDINONES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-11-01 | — | — | WO | claimed |
| US-6436919-B1 | LOCAL ANESTHETICS THAT HAVE LONGER DURATION OF ACTION WHILE REDUCING UNDESIRED SIDE EFFECTS | THERAVANCE INC. | 2002-08-20 | — | — | US | claimed |
| EP-1216243-A1 | QUINAZOLINONES AND ANALOGUES AND THEIR USE AS LOCAL ANESTHETICS | Advanced Medicine, Inc. (US) | 2002-06-26 | — | — | EP | claimed |
| WO-2001025234-A1 | QUINAZOLINONES AND ANALOGUES AND THEIR USE AS LOCAL ANESTHETICS | ADVANCED MEDICINE, INC. (US) | 2001-04-12 | — | — | WO | claimed |
| US-20260098032-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS INC (US) | 2026-04-09 | — | — | US | disclosed |
| US-12570645-B2 | Uses of p53 x-ray co-crystal structures | PMV PHARMACEUTICALS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20260027097-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-12428406-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-12419880-B2 | Companion diagnostic tool for mutant p53 reactivating compounds | PMV PHARMACEUTICALS, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250270209-A1 | LRRK2 INHIBITORS | INTERLINE THERAPEUTICS, INC. | 2025-08-28 | — | — | US | disclosed |
| US-20250091994-A1 | RAS/RAF BINDING INHIBITOR COMPOUND | NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY (JP) | 2025-03-20 | — | — | US | disclosed |
| US-7358249-B2 | Heterocyclic compounds having inhibitory activity against HIV integrase | SHIONOGI & CO., LTD. (JP) | 2008-04-15 | — | — | US | disclosed |
| WO-2008000818-A1 | FLUORINATED INDOLEAMIDES USEFUL AS LIGANDS OF THE ORL-1 RECEPTOR | BRANE DISCOVERY S.R.L. (IT) | 2008-01-03 | — | — | WO | disclosed |
| WO-2007146712-A2 | THERAPY USING CYTOKINE INHIBITORS | KEMIA, INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007056016-A2 | BISAMIDE CYTOKINE INHIBITORS | KEMIA, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| US-6436919-B1 | LOCAL ANESTHETICS THAT HAVE LONGER DURATION OF ACTION WHILE REDUCING UNDESIRED SIDE EFFECTS | THERAVANCE INC. | 2002-08-20 | — | — | US | disclosed |
| EP-1216243-A1 | QUINAZOLINONES AND ANALOGUES AND THEIR USE AS LOCAL ANESTHETICS | Advanced Medicine, Inc. (US) | 2002-06-26 | — | — | EP | disclosed |
| WO-2001025234-A1 | QUINAZOLINONES AND ANALOGUES AND THEIR USE AS LOCAL ANESTHETICS | ADVANCED MEDICINE, INC. (US) | 2001-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250091994-A1 | RAS/RAF BINDING INHIBITOR COMPOUND | BRAF, RAF1, NRAS | ATM 1432/4885ALDH1A1 2352/4885KDM4E 2663/4885 |
| US-12428406-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, KRAS | ATM 115/4885ALDH1A1 1538/4885KDM4E 2994/4885 |
| US-20260027097-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, BRCA1 | ATM 119/4885ALDH1A1 1944/4885KDM4E 385/4885 |
| US-12570645-B2 | Uses of p53 x-ray co-crystal structures | TP53, TP53BP1, ERCC2 | ATM 132/4885ALDH1A1 3910/4885KDM4E 3295/4885 |
| US-20250270209-A1 | LRRK2 INHIBITORS | LRRK2, PARK7, PINK1 | ATM 816/4885ALDH1A1 2142/4885KDM4E 1504/4885 |
| US-20260098032-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, MDM2 | ATM 129/4885ALDH1A1 4027/4885KDM4E 1371/4885 |
| US-12419880-B2 | Companion diagnostic tool for mutant p53 reactivating compounds | TP53, TP53BP1, KRAS | ATM 501/4885ALDH1A1 1835/4885KDM4E 3177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.